A New Generation of Drugs Could Lower Heart Attack Risk for Millions
The episode spotlights a new class of genetic‑silencing drugs targeting elevated lipoprotein(a) (Lp(a)), a hereditary risk factor for heart attacks and strokes, with late‑stage trials from Novartis, Amgen and Eli Lilly poised to reveal efficacy data. Reporters explain how these therapies aim to shut down the liver’s production of Lp(a) and discuss the hurdles of proving that lowering the biomarker translates into meaningful cardiovascular outcomes, noting that insurers and regulators will look for at least a 13‑20% risk reduction. The segment also touches on Ford’s pivot to AI‑focused battery production, Lululemon’s board settlement with founder Chip Wilson, and geopolitical updates on U.S.–Iran negotiations and FIFA ticket pricing investigations.
Mapping Cellular Stress Biology to Tackle Undruggable Targets
In this episode, Daniel Levine interviews Yeremiá Gizarian, co‑founder and CEO of Soleil Therapeutics, about the company’s AI‑driven platform that maps cellular stress responses to discover drugs for traditionally "undruggable" targets. The discussion explains how Soleil flips the conventional drug‑discovery...
The Next Era of Healthcare Is Personal
In this episode, McKinsey’s Eric Kutcher talks with Moderna CEO Stéphane Bancel about how mRNA technology and AI are reshaping healthcare from rapid vaccine development to truly personalized medicines. Bancel explains that mRNA is an "information molecule" that can be programmed...
Beyond Senolytics: Senoadaptive Drugs & Clinical Data on GPX4 Modulation (Dr. Marco Quarta, Rubedo)
In this episode, Dr. Marco Quarta, co‑founder and CSO of Rubedo Life Sciences, discusses the company’s breakthrough first‑in‑class GPX4‑modulating drug RLS1496, which has just reported preliminary Phase 1 basket‑trial data across multiple skin indications. He explains how Rubedo’s AI‑enabled single‑cell multi‑omics...
EXCLUSIVE: Peptides, Fauci & MAHA - What You Need to Know | Daily Pulse
In this episode, host Maria Z interviews Dr. Lynn Finn, a retired infectious disease specialist turned clinical researcher, to unpack the rising popularity and risks of peptide supplements. Dr. Finn explains what peptides are, their potential therapeutic uses, and why...
Big Apple Exclusive: Dr. McCullough Goes Live to Unveil Potential Cancer Breakthrough
In this episode, Dr. Peter McCullough, chief scientific officer of a wellness company, discusses an observational report on the off‑label use of two generic drugs—ivermectin and mebendazole—in cancer patients. The study, now under peer review, found that nearly half of participants...
Remembering J. Craig Venter, PhD
In this tribute episode of Touching Base, host Corinna Singelman and Gen editors John Sterling and Kevin Davis reflect on the life and legacy of biotech pioneer J. Craig Venter, who recently died at 79. They recount Venter's groundbreaking role...
What Impact Could Protein Stabilisation Have for Cancer Patients?
In this episode of the DDW Podcast, CEO Anthony Johnson and CSO Matthew Fyfe discuss OutRun Therapeutics' novel protein‑stabilisation platform, which inhibits specific E3 ubiquitin ligases to prevent degradation of disease‑relevant proteins. Their lead program targets the E6AP ligase to...
Addressing Treatment Gaps in Gout
In this episode, Crystallis Therapeutics CEO James McKay explains the biology of gout, why existing urate‑lowering drugs often fail, and how the company’s next‑generation URAT1 inhibitor, detenurad, aims to close the large treatment gap for moderate‑to‑severe patients. He highlights that...
Redefining Success in Transplant Medicine
In this episode of Signals KOLs, transplant nephrologist Dr. Deirdre Sawinski, industry veteran Steve Risk (SVP Medical Affairs at Veloxys), and patient‑physician Sejal Patel discuss the stagnant long‑term outcomes in kidney transplantation despite excellent short‑term success. They highlight how current...
The Cyborgs Commeth - EP 69 Connor Glass
In this episode, host Ashley Vance talks with Connor Glass, co‑founder and CEO of Phantom Neuro, about the company’s sub‑dermal neural interface that lets amputees control prosthetic limbs using muscle‑derived electrical signals—offering a less invasive alternative to brain‑computer interfaces like...
343. Summary: Can This Nutrient Help Alzheimer's? - Life Extension
In this episode, Dr. Mike and Dr. Crystal discuss a recent pilot study on creatine supplementation as a potential therapy for Alzheimer's disease, featuring insights from lead author Aaron Smith. They explain how creatine, known for its role in muscle...
BREAKING: Senate Investigation Finds FDA Officials Covered-Up 25 COVID Shot Safety Signals
The episode examines a Senate investigation revealing that FDA officials allegedly suppressed about 25 statistically significant safety signals linked to COVID‑19 vaccine adverse events, including serious conditions such as Bell's palsy, cardiac failure, sudden cardiac death, and strokes. It details...
Could This Be the First Parkinson's Disease Modifier?
In this brief episode, the host and a GAIN representative discuss GT02287, a novel allosteric modulator targeting the glucocerebrosidase (GCase) enzyme, as a potential disease‑modifying therapy for Parkinson’s disease. They explain how the drug stabilizes the misfolded enzyme’s shape, enhancing...
The Machine Ethics Podcast: Organoid Computing with Dr Ewelina Kurtys
In this episode, host discusses organoid-based biocomputing with neuroscientist‑turned‑entrepreneur Dr. Ewelina Kurtys, who advises the Swiss startup Final Spark. They explain how cultured cortical organoids of ~10,000 neurons are wired to electrodes to send and read electrical signals, highlighting the...